Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The
efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are
limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family
and recently, its immunomodulatory and anti-apoptosis function has been replied to several
immune diseases and degenerative diseases. This study aims to explore the efficacy and safety
of minocycline for CME.